Rich US subsidies may hobble Canada’s clean-fuel efforts

By Rod Nickel WINNIPEG, Manitoba (Reuters) – Canadian biofuels producers are threatening to build their next projects in the United States to cash in on rich subsidies for clean fuel and stay competitive, a move that could cost Canada C$10 billion ($7.5 billion) of investment and undermine Prime Minister Justin Trudeau’s efforts to build a…

Read More

German stocks lead gains in Europe, all eyes on central bank meetings

By Shreyashi Sanyal and Bansari Mayur Kamdar (Reuters) -Germany’s DAX index led gains among its European peers on Monday, boosted by Adidas shares after an analyst upgrade, while investor focus was largely on major central bank policy meetings scheduled through the week. The pan-European STOXX 600 index closed 0.2% higher, with the DAX up 0.9%….

Read More

Carnival leads gains in cruise stocks as analysts eye strong travel demand

By Chibuike Oguh NEW YORK (Reuters) – Shares of Carnival Corp and Norwegian Cruise Line Holdings Ltd jumped on Monday, and were among the top S&P 500 performers, as analysts anticipate continuing growth in travel demand from customers. Bookings across the cruise industry, which were hit hard during the pandemic, have now reached historical levels…

Read More

Thyssenkrupp pulls trigger on long-awaited IPO of hydrogen division Nucera

By Christoph Steitz and Tom Käckenhoff FRANKFURT/DUESSELDORF (Reuters) -Thyssenkrupp launched on Monday the long-awaited listing of its hydrogen division Nucera, suggesting its new chief executive intends to waste no time in reviving the fortunes of the embattled conglomerate. Thyssenkrupp Nucera, a 66:34 joint venture with Italy’s De Nora, is targeting proceeds of up to 600…

Read More

Biogen rises as FDA panel backs Alzheimer’s drug, easing safety concerns

(Reuters) – Biogen’s shares rose 2% on Monday as a unanimous backing of its Alzheimer’s drug by the U.S. health regulator’s advisers strengthened the case for a traditional approval with no major new safety warnings. The Food and Drug Administration’s advisory panel unanimously agreed that a late-stage trial of the drug Leqembi, developed with partner…

Read More